Related Experiment Video
Updated: May 2, 2026
A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice
Published on: November 15, 2019
Risk and Dose-Response Relationship for Pentosan Polysulfate Sodium Maculopathy: A Systematic Review and
Brendan K Tao1, Korolos Sawires2, Kate Lim2
1Department of Ophthalmology & Vision Science, University of Toronto, Toronto, Ontario, Canada.
Topic:
To determine the pooled relative risk (RR) of pentosan polysulfate sodium maculopathy (PPSM) in patients using pentosan polysulfate sodium (PPS) and model the dose-response relationship of this association from existing literature.
Clinical Relevance:
Pentosan polysulfate sodium maculopathy is an acquired, progressive retinal pigmentary disease associated with oral PPS use. Although several observational studies suggest a dose-response relationship of this association, to date, there remains no literature-pooled synthesis on the risk of PPSM across strata of cumulative dose.
Methods:
Systematic review and meta-analysis (CRD42024623179). Medline, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to September 15, 2024. We included studies reporting the incidence of PPS-associated maculopathy and including cumulative PPS dose information. Two independent reviewers completed study screening, data extraction, and risk of bias (ROB) assessment using the ROB in nonrandomized studies of exposures tool, and a third reviewer was consulted to resolve conflicts. The primary outcome was the RR of PPSM among patients exposed to PPS compared with nonexposed individuals, stratified by cumulative PPS dose.
Results:
We included 5 studies encompassing 141 785 patients and 6432 PPSM cases. The linear dose-response regression model estimated a 0.1% increase in RR of maculopathy per g increase in cumulative PPS dose (log-transformed RR = 0.00101; 95% confidence interval, 0.0005-0.0015; P < 0.0001). Patients with cumulative doses ≥2000 g exhibited an RR of 7.39 (95% confidence interval, 4.17-13.10), while those with a dose between 1 and 500 g had an RR of 1.65 (95% confidence interval, 1.12-2.43) compared with nonexposed individuals. Subgroup analysis excluding high-risk studies demonstrated consistent findings, with reduced heterogeneity (I2 = 63.7%).
Conclusion:
Moderate certainty evidence supports a dose-dependent relationship between PPS exposure and PPSM risk, whereas higher cumulative doses significantly increase maculopathy risk. This result supports that patients should be tapered to an effective minimal dose and that they should be subject to interval maculopathy screening, especially for patients with greater cumulative dose. Future research should incorporate patient-level data to better control for potential confounding.
Financial Disclosure(S):
The authors have no proprietary or commercial interest in any materials discussed in this article.
Insights
Pentosan polysulfate sodium maculopathy (PPSM) risk increases with higher cumulative doses of pentosan polysulfate sodium (PPS). This meta-analysis confirms a dose-response relationship, highlighting the need for careful patient monitoring and dose management.
Area of Science:
- Ophthalmology
- Pharmacovigilance
- Retinal Diseases
Background:
- Pentosan polysulfate sodium (PPS) is used for various conditions, but its association with maculopathy (PPSM) is a growing concern.
- Existing observational studies suggest a link between PPS dose and maculopathy risk, but a pooled analysis was lacking.
Purpose of the Study:
- To conduct a systematic review and meta-analysis to determine the pooled relative risk (RR) of pentosan polysulfate sodium maculopathy (PPSM).
- To model the dose-response relationship between cumulative pentosan polysulfate sodium (PPS) dose and the risk of developing PPSM.
Main Methods:
- Systematic review and meta-analysis of studies reporting PPSM incidence and cumulative PPS dose.
- Searched Medline, Embase, and Cochrane Central Register of Controlled Trials up to September 15, 2024.
- Included 5 studies with 141,785 patients and 6432 PPSM cases; assessed risk of bias.
Main Results:
- A linear dose-response model indicated a 0.1% increase in maculopathy RR per gram increase in cumulative PPS dose.
- Patients with cumulative doses ≥2000 g had an RR of 7.39 (95% CI, 4.17-13.10) compared to nonexposed.
- Even lower doses (1-500 g) showed an increased RR of 1.65 (95% CI, 1.12-2.43).
Conclusions:
- Moderate certainty evidence supports a dose-dependent relationship between PPS exposure and PPSM risk.
- Higher cumulative PPS doses significantly elevate the risk of maculopathy.
- Recommendations include tapering PPS to the minimal effective dose and implementing regular maculopathy screening, especially for high-cumulative dose patients.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:24Drug Toxicity: Dose-Dependent Reactions